Resveratrol inhibits the phosphatidylinositide 3‑kinase/protein kinase B/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line

Sui,Tao; Ma,Li; Bai,Xue; Li,Qing; Xu,Xinnv

doi:10.3892/ol.2014.2014

Resveratrol inhibits the phosphatidylinositide 3‑kinase/protein kinase B/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line

Authors:
- Tao Sui
- Li Ma
- Xue Bai
- Qing Li
- Xinnv Xu
View Affiliations

Affiliations: Department of Hematology, Tianjin First Center Hospital, Tianjin 300192, P.R. China, Key Laboratory for Critical Care Medicine of the Ministry of Health, Tianjin First Center Hospital, Tianjin 300192, P.R. China
Published online on: March 28, 2014 https://doi.org/10.3892/ol.2014.2014
Pages: 2093-2098

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Resveratrol inhibits the initiation, promotion and progression of tumors, however, the mechanism by which resveratrol inhibits the proliferation of the human chronic myeloid leukemia K562 cell line remains unclear. The present study was conducted to investigate the effect of resveratrol on the activation of the phosphatidylinositide 3‑kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling cascade in K562 cells. Resveratrol showed significant cytotoxic effects and induced apoptosis in K562 cells in a dose‑ and time‑dependent manner. In addition, resveratrol attenuated the phosphorylation of PI3K, Akt and mTOR in the K562 cells. Furthermore, the selected inhibitors of PI3K (LY294002), Akt (SH‑6) and mTOR (rapamycin) enhanced the effects of resveratrol in K562 cells. In addition, cyclin D1 levels were found to decrease and the activation of caspase‑3 was observed. Resveratrol was also found to significantly attenuate the phosphorylation of the downstream molecules, p70S6K and 4EBP1. These results suggested that the downregulation of the PI3K/Akt/mTOR signaling cascades may be a crucial mediator in the inhibition of proliferation and induction of apoptosis by resveratrol in K562 cells.

View Figures

View References

1	Chandra HS, Heisterkamp NC, Hungerford A, Morrissette JJ, Nowell PC, Rowley JD and Testa JR: Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet. 204:171–179. 2011. View Article : Google Scholar : PubMed/NCBI
2	Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood. 96:3343–3356. 2000.PubMed/NCBI
3	Hantschel O and Superti-Furga G: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 5:33–44. 2004. View Article : Google Scholar : PubMed/NCBI
4	Sattler M and Griffin JD: Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 40(Suppl 2): S4–S10. 2003. View Article : Google Scholar
5	Barrett D, Brown VI, Grupp SA and Teachey DT: Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs. 14:299–316. 2012.PubMed/NCBI
6	Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 191:977–984. 2000. View Article : Google Scholar
7	Pene-Dumitrescu T and Smithgall TE: Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem. 285:21446–21457. 2010. View Article : Google Scholar : PubMed/NCBI
8	Baum KJ and Ren R: Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol. 1:52008. View Article : Google Scholar : PubMed/NCBI
9	Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, et al: A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood. 107:2507–2516. 2006. View Article : Google Scholar : PubMed/NCBI
10	Baran Y and Saydam G: Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. J Blood Med. 3:139–150. 2012. View Article : Google Scholar : PubMed/NCBI
11	Mauro MJ and Deininger MW: Chronic myeloid leukemia in 2006: a perspective. Haematologica. 91:1522006.PubMed/NCBI
12	Shah NP and Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 22:7389–7395. 2003. View Article : Google Scholar : PubMed/NCBI
13	Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99:3530–3539. 2002. View Article : Google Scholar : PubMed/NCBI
14	Soleas GJ, Diamandis EP and Goldberg DM: Resveratrol: a molecule whose time has come? And gone? Clin Biochem. 30:91–113. 1997. View Article : Google Scholar : PubMed/NCBI
15	Jang DS, Kang BS, Ryu SY, Chang IM, Min KR and Kim Y: Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem Pharmacol. 57:705–712. 1999. View Article : Google Scholar : PubMed/NCBI
16	Inoue H, Jiang XF, Katayama T, Osada S, Umesono K and Namura S: Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett. 352:203–206. 2003. View Article : Google Scholar : PubMed/NCBI
17	Yu W, Fu YC and Wang W: Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 113:752–759. 2012. View Article : Google Scholar : PubMed/NCBI
18	Delmas D, Solary E and Latruffe N: Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem. 18:1100–1121. 2011. View Article : Google Scholar : PubMed/NCBI
19	Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, et al: Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 15:1613–1615. 2001.PubMed/NCBI
20	Mgbonyebi OP, Russo J and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol. 12:865–869. 1998.PubMed/NCBI
21	Ahmad N, Adhami VM, Afaq F, Feyes DK and Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 7:1466–1473. 2001.PubMed/NCBI
22	Dörrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 61:4731–4739. 2001.
23	Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl. 28:282–293. 2007. View Article : Google Scholar : PubMed/NCBI
24	Fulda S and Debatin KM: Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer. 41:786–798. 2005. View Article : Google Scholar : PubMed/NCBI
25	Shankar S, Siddiqui I and Srivastava RK: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem. 304:273–285. 2007. View Article : Google Scholar
26	Shankar S, Singh G and Srivastava RK: Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
27	Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC, Croc L, et al: Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther. 4:554–561. 2005. View Article : Google Scholar : PubMed/NCBI
28	Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al: Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol. 8:25–33. 2009.PubMed/NCBI
29	Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr. 21:381–406. 2001. View Article : Google Scholar : PubMed/NCBI
30	Quoc Trung L, Espinoza JL, Takami A and Nakao S: Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One. 8:e551832013.PubMed/NCBI
31	Miki H, Uehara N, Kimura A, Sasaki T, Yuri T, Yoshizawa K and Tsubura A: Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int J Oncol. 40:1020–1028. 2012.PubMed/NCBI
32	Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M and Al-Kuraya KS: Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One. 6:e247032011. View Article : Google Scholar : PubMed/NCBI
33	Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M and Chen H: Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol. 18:1506–1511. 2011. View Article : Google Scholar : PubMed/NCBI
34	Chen Q, Ganapathy S, Singh KP, Shankar S and Srivastava RK: Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One. 5:e152882010. View Article : Google Scholar : PubMed/NCBI
35	Leong CW, Wong CH, Lao SC, Leong EC, Lao IF, Law PT, et al: Effect of resveratrol on proliferation and differentiation of embryonic cardiomyoblasts. Biochem Biophys Res Commun. 360:173–180. 2007. View Article : Google Scholar : PubMed/NCBI
36	Kaminski J, Lançon A, Aires V, Limagne E, Tili E, Michaille JJ and Latruffe N: Resveratrol initiates differentiation of mouse skeletal muscle-derived C2C12 myoblasts. Biochem Pharmacol. 84:1251–1259. 2012. View Article : Google Scholar
37	Yu XM, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M and Chen H: Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther. 12:1276–1287. 2013. View Article : Google Scholar : PubMed/NCBI
38	Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol. 8:393–412. 2008. View Article : Google Scholar : PubMed/NCBI
39	Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
40	Wetzker R and Rommel C: Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des. 10:1915–1922. 2004. View Article : Google Scholar : PubMed/NCBI
41	Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004.PubMed/NCBI
42	Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene. 22:8983–8998. 2003. View Article : Google Scholar : PubMed/NCBI
43	Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
44	Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L and McCubrey JA: Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs. 18:1333–1349. 2009. View Article : Google Scholar : PubMed/NCBI
45	Gao N, Zhang Z, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 310:1124–1132. 2003. View Article : Google Scholar : PubMed/NCBI
46	Sun C, Hu Y, Liu X, Wu T, Wang Y, He W and Wei W: Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet. 165:9–19. 2006. View Article : Google Scholar